At present, clinical studies have confirmed that SGLT2 inhibitor can inhibit or reduce renal and hepatic fibrosis, and related animal experiments have also confirmed that SGLT2 inhibitor has a good inhibitory effect on myocardial fibrosis in rats [5, 6]. This evidence concerns the gene SLC5A2 and Myocardial fibrosis.